Form 8-K · Current Report · Filed 2025-04-24
Merck Reports First-Quarter 2025 Financial Results
Merck & Co., Inc. reported first-quarter 2025 financial results, showing total worldwide sales of $15.5 billion, a 2% decrease from the prior year. GAAP EPS was $2.01, and non-GAAP EPS was $2.22. Keytruda sales grew by 4%, while Gardasil/Gardasil 9 sales declined by 41%. Merck also presented pivotal data from various clinical trials and provided a full-year 2025 financial outlook.
- Filer
- Merck & Co., Inc. MRK · NYSE
- Filed
- Accession
- 0001104659-25-038301
- CIK
- 0000310158
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$78.74
Next session
+5.1%
Since filing
+65.4%
Latest close
$130.20
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from MRK reporting the same item, with the next session's move:
Exhibits (2)
About Merck & Co., Inc.
Merck & Co., Inc. is a prominent player in the global pharmaceutical industry. It is primarily focused on the research, development, production, and marketing of drugs and vaccines. Known for its strong emphasis on innovative health solutions, Merck develops treatments and vaccines for a variety of diseases affecting humans and animals. Key areas include oncology, infectious diseases, diabetes, and vaccines, reflecting its commitment to addressing critical health challenges worldwide. The company operates in several strategic regions, exporting its advanced therapies to meet healthcare needs across different markets. With a robust pipeline of new products and significant investment in research and development, Merck plays a vital role in advancing medical breakthroughs and enhancing patient care. Beyond pharmaceuticals, Merck is involved in animal health, providing veterinary vaccines and services, contributing to agricultural productivity and food security. The company's ongoing efforts in groundbreaking research and public health initiatives underscore its importance in the healthcare sector.
Never miss another MRK filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.